AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28981596 — intervention group
Group type: EXPERIMENTAL
Intervention: Early mobilization postoperative programme based on supervised aerobic exercise, resistance and flexibility training
Number of subjects: 108
Study 28981596 — intervention group
Group type: COMPARATOR
Intervention: Standard rehabilitation care
Number of subjects: 108
Study 25839137 — intervention group
Group type: EXPERIMENTAL
Intervention: SAR(10G)=2 W/kg
Number of subjects: 24
Study 25839137 — intervention group
Group type: EXPERIMENTAL
Intervention: SAR(10G)=0.2 W/kg
Number of subjects: 24
Study 25839137 — intervention group
Group type: COMPARATOR
Intervention: Sham
Number of subjects: 24
Study 24206457 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with lisinopril (10 to 40 mg per day)
Number of subjects: 1448
Study 24206457 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy with losartan (100 mg per day)
Number of subjects: 1448
Study 24206457 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 1448
Study 21292243 — intervention group
Group type: EXPERIMENTAL
Intervention: Cue-exposure treatment (CET)
Number of subjects: 30
Study 21292243 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 19636278 — intervention group
Group type: EXPERIMENTAL
Intervention: motavizumab (3, 15, or 30 mg/kg intravenously)
Number of subjects: 0
Study 19636278 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study 17555930 — intervention group
Group type: EXPERIMENTAL
Intervention: Transesophageal echocardiography (TEE)
Number of subjects: 39
Study 17555930 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time 3-dimensional echocardiography (RT-3DE)
Number of subjects: 39
Study 15082726 — intervention group
Group type: COMPARATOR
Intervention: D1 lymph node dissection
Number of subjects: 1078
Study 15082726 — intervention group
Group type: EXPERIMENTAL
Intervention: D2 lymph node dissection
Number of subjects: 1078
Study 11383457 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment based on correlation between tumor size and stage of molecular-genetical disorders
Number of subjects: 0
Study 9401505 — intervention group
Group type: EXPERIMENTAL
Intervention: Test Diet (TD): a combination of a semi-solid pap (maize flour, black beans, oil) and a liquid gruel, Incaparina (maize flour, cotton seed flour, sugar), in addition to breast-milk and other home foods (n = 45 episodes) for 14 days
Number of subjects: 90
Study 9401505 — intervention group
Group type: COMPARATOR
Intervention: Usual home feeding (HF) (n = 54 episodes)
Number of subjects: 90
Study 9401505 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (TD and HF)
Number of subjects: 90
Study 8123349 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive counseling protocol combined with a 2-week follow-up mailout; 6-minute proactive telephone counseling.
Number of subjects: 1831
Study 8123349 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive counseling protocol (intervention) at one test site.
Number of subjects: 1831
Study 8123349 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual service without proactive counseling).
Number of subjects: 1831
Study 2441156 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous injection of 100 micrograms of alpha‐hANP
Number of subjects: 8
Study 2441156 — intervention group
Group type: COMPARATOR
Intervention: Control subcutaneous injection (placebo)
Number of subjects: 8
Study 2697238 — intervention group
Group type: EXPERIMENTAL
Intervention: pH-adjusted 2-chloroprocaine in sitting position
Number of subjects: 4
Study 2697238 — intervention group
Group type: EXPERIMENTAL
Intervention: pH-adjusted 2-chloroprocaine in supine position
Number of subjects: 4
Study 2697238 — intervention group
Group type: COMPARATOR
Intervention: Control solution in sitting position
Number of subjects: 4
Study 2697238 — intervention group
Group type: COMPARATOR
Intervention: Control solution in supine position
Number of subjects: 4
Study 31137991 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy drink A
Number of subjects: 34
Study 31137991 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy drink B
Number of subjects: 34
Study 31137991 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 31137991 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy drinks (A and B combined)
Number of subjects: 34
Study 28557655 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic Acid (HA) eye drops
Number of subjects: 40
Study 28557655 — intervention group
Group type: EXPERIMENTAL
Intervention: Crosslinked Hyaluronic Acid (CLHA) eye drops
Number of subjects: 40
Study 28557655 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 40
Study 28557655 — intervention group
Group type: COMPARATOR
Intervention: Comparison of SRI and SAI between SSDE and control groups
Number of subjects: 40
Study 24910149 — intervention group
Group type: EXPERIMENTAL
Intervention: Identity priming
Number of subjects: 2
Study 24910149 — intervention group
Group type: EXPERIMENTAL
Intervention: N400 priming
Number of subjects: 2
Study 24910149 — intervention group
Group type: EXPERIMENTAL
Intervention: Priming
Number of subjects: 2
Study 24910149 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior-P1 amplitude
Number of subjects: 2
Study 24910149 — intervention group
Group type: EXPERIMENTAL
Intervention: Frontal/temporal-P1 amplitude
Number of subjects: 2
Study 24228867 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy and occupational therapy delivered six days a week (Monday through Saturday)
Number of subjects: 996
Study 24228867 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy and occupational therapy delivered five days a week (Monday through Friday)
Number of subjects: 996
Study 21604466 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical treatment with clarithromycin, alkaline nasal douche, and intranasal mometasone furoate for 12 weeks
Number of subjects: 72
Study 21604466 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment (adenoidectomy, tonsillectomy, or ESS)
Number of subjects: 72
Study 21604466 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenoidectomy (n = 19), adenoidectomy and tonsillectomy (n = 10), ESS (n = 8)
Number of subjects: 72
Study 18097460 — intervention group
Group type: EXPERIMENTAL
Intervention: ThinOptX lens
Number of subjects: 58
Study 18097460 — intervention group
Group type: COMPARATOR
Intervention: Acrysof lens
Number of subjects: 58
Study 17100757 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccination
Number of subjects: 0
Study 15503036 — intervention group
Group type: EXPERIMENTAL
Intervention: Amplatz thrombectomy device (ATD)
Number of subjects: 174
Study 15503036 — intervention group
Group type: COMPARATOR
Intervention: Surgical thromboembolectomy (ST)
Number of subjects: 174
Study 11579852 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HOT), administered once daily for 10 days
Number of subjects: 50
Study 11579852 — intervention group
Group type: COMPARATOR
Intervention: Intravenous vasodilator, administered for 10 days
Number of subjects: 50
Study 11579852 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HOT)
Number of subjects: 50
Study 11579852 — intervention group
Group type: COMPARATOR
Intervention: Intravenous vasodilator
Number of subjects: 50
Study 9383502 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical Skin Protectant (TSP)
Number of subjects: 10
Study 9383502 — intervention group
Group type: COMPARATOR
Intervention: Control (no TSP application)
Number of subjects: 10
Study 7970925 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized furosemide (1.0 mg/kg)
Number of subjects: 29
Study 7970925 — intervention group
Group type: COMPARATOR
Intervention: Aerosolized normal saline (placebo)
Number of subjects: 29
Study 7970925 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized albuterol (0.15 mg/kg)
Number of subjects: 29
Study 7970925 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of albuterol and furosemide
Number of subjects: 29
Study 3297594 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroxydibutylether (DHBE), 900 mg daily
Number of subjects: 0
Study 3297594 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30071296 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily IGRT
Number of subjects: 470
Study 30071296 — intervention group
Group type: COMPARATOR
Intervention: Weekly IGRT
Number of subjects: 470
Study 27070112 — intervention group
Group type: EXPERIMENTAL
Intervention: Paper tape applied to blister-prone areas or randomly selected locations on the foot
Number of subjects: 128
Study 27070112 — intervention group
Group type: COMPARATOR
Intervention: Untaped areas of the same foot (Control)
Number of subjects: 128
Study 24489726 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 minute WBC at -135°C
Number of subjects: 14
Study 24489726 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 minutes WBC at -135°C
Number of subjects: 14
Study 24489726 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 minutes WBC at -135°C
Number of subjects: 14
Study 24489726 — intervention group
Group type: EXPERIMENTAL
Intervention: WBC at -135°C
Number of subjects: 14
Study 23075398 — intervention group
Group type: EXPERIMENTAL
Intervention: Meal preparation training combined with pedometer-based step count monitoring
Number of subjects: 72
Study 19845846 — intervention group
Group type: EXPERIMENTAL
Intervention: On-demand tadalafil (N = 2,824)
Number of subjects: 3935
Study 19845846 — intervention group
Group type: COMPARATOR
Intervention: Placebo (N = 1,111)
Number of subjects: 3935
Study 17384766 — intervention group
Group type: EXPERIMENTAL
Intervention: Formaldehyde exposure (500 microg/m(3))
Number of subjects: 12
Study 17384766 — intervention group
Group type: COMPARATOR
Intervention: Air-only exposure (control)
Number of subjects: 12
Study 17384766 — intervention group
Group type: EXPERIMENTAL
Intervention: Formaldehyde exposure
Number of subjects: 12
Study 16300696 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalbuphine 0.2 mg/kg
Number of subjects: 40
Study 16300696 — intervention group
Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 40
Study 12843909 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical ventilation
Number of subjects: 15
Study 12843909 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous breathing
Number of subjects: 15
Study 12843909 — intervention group
Group type: COMPARATOR
Intervention: Supine posture
Number of subjects: 15
Study 12843909 — intervention group
Group type: COMPARATOR
Intervention: Recumbent 30 degrees posture
Number of subjects: 15
Study 10051239 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic search for sinusitis by CT scan (study group)
Number of subjects: 399
Study 10051239 — intervention group
Group type: COMPARATOR
Intervention: No systematic search for sinusitis (control group)
Number of subjects: 399
Study 8554498 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil (1200 mg/day, n = 15)
Number of subjects: 29
Study 8554498 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin (10 or 20 mg, n = 10 and 4 respectively)
Number of subjects: 29
Study 1785180 — intervention group
Group type: EXPERIMENTAL
Intervention: Live attenuated and inactivated virion divaccines of influenza A (H1N1 + H3N2) and influenza B vaccines
Number of subjects: 0
Study 1785180 — intervention group
Group type: EXPERIMENTAL
Intervention: Lectin test (microvariant)
Number of subjects: 0
Study 7178879 — intervention group
Group type: EXPERIMENTAL
Intervention: Mastectomy and chemoimmunotherapy (CT + IT)
Number of subjects: 1985
Study 7178879 — intervention group
Group type: COMPARATOR
Intervention: Mastectomy
Number of subjects: 1985
Study 7178879 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrospective analysis
Number of subjects: 1985
Study 31453982 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol (2660 mg total over 2 weeks)
Number of subjects: 0
Study 31453982 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29603202 — intervention group
Group type: EXPERIMENTAL
Intervention: Couples-based health behavior intervention
Number of subjects: 348
Study 29603202 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly detailed in the abstract)
Number of subjects: 348
Study 26841782 — intervention group
Group type: EXPERIMENTAL
Intervention: Caseload midwifery
Number of subjects: 2314
Study 26841782 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 2314
Study 24755888 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed (500 mg/m² d1) and either cisplatin (75 mg/m² d1) or carboplatin (AUC = 5 d1) plus gefitinib (250 mg/d on days 3 to 16 of a 3-week cycle) (PC-G)
Number of subjects: 0
Study 24755888 — intervention group
Group type: COMPARATOR
Intervention: Pemetrexed-platinum (PC) alone
Number of subjects: 0
Study 24755888 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed (500 mg/m² d1) and either cisplatin (75 mg/m² d1) or carboplatin (AUC = 5 d1) plus gefitinib (PC-G)
Number of subjects: 0
Study 22763078 — intervention group
Group type: EXPERIMENTAL
Intervention: eCG on Day 22 post AI (400 IU)
Number of subjects: 337
Study 22763078 — intervention group
Group type: EXPERIMENTAL
Intervention: hCG on Day 29 (2500 IU)
Number of subjects: 337
Study 22763078 — intervention group
Group type: EXPERIMENTAL
Intervention: eCG on Day 22 post AI (in low body condition cows)
Number of subjects: 337
Study 22763078 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 337
Study 19692943 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence based medicine methodology
Number of subjects: 0
Study 19692943 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical protocol conducting
Number of subjects: 0
Study 19692943 — intervention group
Group type: EXPERIMENTAL
Intervention: Vital medicines listing
Number of subjects: 0
Study 19692943 — intervention group
Group type: EXPERIMENTAL
Intervention: Lists of refundable medicines
Number of subjects: 0
Study 17999276 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol supplementation during the luteal phase
Number of subjects: 0
Study 17999276 — intervention group
Group type: COMPARATOR
Intervention: Control group (no estradiol supplementation)
Number of subjects: 0
Study 15307690 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese medicine 'xiao cuo fang' combined with 0.1% adapalene gel
Number of subjects: 133
Study 15307690 — intervention group
Group type: COMPARATOR
Intervention: 0.03% retinoic acid cream
Number of subjects: 133
Study 12210667 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducation (PE) program
Number of subjects: 85
Study 12210667 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual
Number of subjects: 85
Study 9794097 — intervention group
Group type: EXPERIMENTAL
Intervention: Acipimox (250 mg/day, four times daily)
Number of subjects: 50
Study 9794097 — intervention group
Group type: EXPERIMENTAL
Intervention: Acipimox plus intralipid
Number of subjects: 50
Study 11541496 — intervention group
Group type: EXPERIMENTAL
Intervention: Declarative preview group (verbal information about workload manipulation)
Number of subjects: 18
Study 11541496 — intervention group
Group type: EXPERIMENTAL
Intervention: Procedural preview group (verbal information and practice under high-workload conditions)
Number of subjects: 18
Study 11541496 — intervention group
Group type: COMPARATOR
Intervention: No-preview group (no information about workload manipulation)
Number of subjects: 18
Study 2572038 — intervention group
Group type: EXPERIMENTAL
Intervention: Broxaterol (0.6-1.2 mg/day by metered dose inhaler or 0.5-1.5 mg/day orally)
Number of subjects: 274
Study 2572038 — intervention group
Group type: COMPARATOR
Intervention: Broxaterol nebulizer solution
Number of subjects: 274
Study 2572038 — intervention group
Group type: COMPARATOR
Intervention: Broxaterol by metered dose inhaler
Number of subjects: 274
Study 2572038 — intervention group
Group type: EXPERIMENTAL
Intervention: Broxaterol
Number of subjects: 274
Study 20912 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomidate 0.3 mg/kg with diazepam and atropine
Number of subjects: 0
Study 20912 — intervention group
Group type: COMPARATOR
Intervention: Etomidate 0.3 mg/kg with papaveretum and hyoscine
Number of subjects: 0
Study 31452049 — intervention group
Group type: EXPERIMENTAL
Intervention: Dance-movement intervention (DMI)
Number of subjects: 99
Study 31452049 — intervention group
Group type: COMPARATOR
Intervention: Control (life-as-usual)
Number of subjects: 99
Study 27126617 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional exercise+usual care group (n=32)
Number of subjects: 63
Study 27126617 — intervention group
Group type: COMPARATOR
Intervention: Usual care group (control, n=31)
Number of subjects: 63
Study 26037626 — intervention group
Group type: EXPERIMENTAL
Intervention: Real electro-acupuncture
Number of subjects: 160
Study 26037626 — intervention group
Group type: COMPARATOR
Intervention: Sham electro-acupuncture (non-insertion technique)
Number of subjects: 160
Study 23951700 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexpanthenol pastilles
Number of subjects: 120
Study 23951700 — intervention group
Group type: COMPARATOR
Intervention: Cold dissection technique
Number of subjects: 120
Study 23951700 — intervention group
Group type: COMPARATOR
Intervention: Thermal welding technique
Number of subjects: 120
Study 22057874 — intervention group
Group type: EXPERIMENTAL
Intervention: Flex-Tip ETT
Number of subjects: 200
Study 22057874 — intervention group
Group type: COMPARATOR
Intervention: Mallinckrodt Hi-Lo ETT
Number of subjects: 200
Study 19832806 — intervention group
Group type: EXPERIMENTAL
Intervention: Asenapine 5 or 10 mg twice daily
Number of subjects: 504
Study 19832806 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine 5 to 20 mg once daily
Number of subjects: 504
Study 19832806 — intervention group
Group type: COMPARATOR
Intervention: Placebo/Asenapine
Number of subjects: 504
Study 19832806 — intervention group
Group type: EXPERIMENTAL
Intervention: Asenapine
Number of subjects: 504
Study 19832806 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 504
Study 17256104 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser alone
Number of subjects: 90
Study 17256104 — intervention group
Group type: COMPARATOR
Intervention: Acid etching alone
Number of subjects: 90
Study 17256104 — intervention group
Group type: COMPARATOR
Intervention: Bur and etching
Number of subjects: 90
Study 15072175 — intervention group
Group type: EXPERIMENTAL
Intervention: Interviewer administered CRQ (CRQ-IA)
Number of subjects: 71
Study 15072175 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered CRQ (CRQ-SA)
Number of subjects: 71
Study 15072175 — intervention group
Group type: COMPARATOR
Intervention: Standardised dyspnoea domain
Number of subjects: 71
Study 11299062 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfusion to a level of 100 g/l
Number of subjects: 0
Study 11299062 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrictive transfusion strategy
Number of subjects: 0
Study 9512851 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron (2.5 mg)
Number of subjects: 90
Study 9512851 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol (1.25 mg)
Number of subjects: 90
Study 9512851 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide (10 mg)
Number of subjects: 90
Study 8736239 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-micrograms dose of Pre S recombinant vaccine
Number of subjects: 105
Study 8736239 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-micrograms dose of Pre S recombinant vaccine
Number of subjects: 105
Study 8736239 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre S recombinant vaccine
Number of subjects: 105
Study 2323591 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride (10 cases)
Number of subjects: 20
Study 2323591 — intervention group
Group type: COMPARATOR
Intervention: Placebo (10 cases)
Number of subjects: 20
Study 7375913 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen (2 mg daily for two or three weeks)
Number of subjects: 16
Study 30797161 — intervention group
Group type: EXPERIMENTAL
Intervention: Focused-incentive group
Number of subjects: 0
Study 30797161 — intervention group
Group type: EXPERIMENTAL
Intervention: Split-incentive group
Number of subjects: 0
Study 28904966 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 μg/kg oral dexmedetomidine (DEX) in apple juice
Number of subjects: 100
Study 28904966 — intervention group
Group type: COMPARATOR
Intervention: apple juice (control)
Number of subjects: 100
Study 25825013 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide treatment (1.8mg/day subcutaneously)
Number of subjects: 90
Study 23347348 — intervention group
Group type: EXPERIMENTAL
Intervention: Flapless surgery
Number of subjects: 24
Study 23347348 — intervention group
Group type: COMPARATOR
Intervention: Flap surgery (control group)
Number of subjects: 24
Study 21272039 — intervention group
Group type: EXPERIMENTAL
Intervention: Shampoo 1 (0.5% piroctone olamine and 0.45% climbazole)
Number of subjects: 0
Study 21272039 — intervention group
Group type: COMPARATOR
Intervention: Shampoo 2 (1% zinc pyrithione)
Number of subjects: 0
Study 19761715 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole (40 mg) + Acetylsalicylic acid (325 mg)
Number of subjects: 55
Study 19761715 — intervention group
Group type: COMPARATOR
Intervention: Acetylsalicylic acid (325 mg) alone
Number of subjects: 55
Study 19761715 — intervention group
Group type: COMPARATOR
Intervention: Esomeprazole (40 mg) alone
Number of subjects: 55
Study 17634483 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib 50 mg daily in cohort 1
Number of subjects: 55
Study 17634483 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib 100 mg daily in cohort 2
Number of subjects: 55
Study 17634483 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib 75 mg daily in cohort 2
Number of subjects: 55
Study 17634483 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib 150 mg daily in cohort 3
Number of subjects: 55
Study 17634483 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib clearance in cohort 1
Number of subjects: 55
Study 17634483 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib clearance in cohort 1a
Number of subjects: 55
Study 17634483 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib clearance in cohort 2
Number of subjects: 55
Study 17634483 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib clearance in cohort 3
Number of subjects: 55
Study 14990394 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril-based active treatment
Number of subjects: 6105